Clinical trials are a large part of the medical process in America and Western Europe, but the practice hasn’t really caught on beyond those territories. Pharmaceutical and biotech companies depend on the continuing growth of medical science provided by the innovations of clinical trials.
But, the pace of trials is slow, and analysing the results even more so. It’s a situation that necessitates more locations for clinical trials to expedite the process and create same-time comparisons of results.
Recent surveys show that the need for more facilities conducting clinical trials are being heeded as more trials outside are conducted outside the US and Western Europe. Paid clinical trials are on a quick rise in Asia, specifically in Japan and China specifically. These countries are followed by Eastern Europe, South America, and South-East Asia.
The fact that more than a third of emerging markets in the above regions are beginning to conduct clinical trials will have a significant effect on medical science and industry decisions. More than half of the respondents to a survey that showed these figures said they are heavily influenced by the status of emerging markets.
The only reservation remaining are the regulations governing clinical trials in other countries. With enthusiastic attention turned on these emerging regions, though, implementation of standardised regulations should be a small matter in the years to come.
